Drug Profile
Tominersen - Ionis Pharmaceuticals
Alternative Names: HTT ASO; IONIS-HTTRx; ISIS-443139; ISIS-HTT Rx; RG 6042; RO-7234292Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals; Roche
- Class Antisense oligonucleotides; Neuroprotectants
- Mechanism of Action HD protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Huntington's disease
Most Recent Events
- 21 Jun 2023 Roche plans to file regulatory application for Huntington’s disease, in or after 2026 (Roche pipeline, June 2023)
- 19 Jan 2023 Roche initiates phase II GENERATION HD2 for Huntington's-disease in USA (NCT05686551)
- 09 Nov 2022 Roche plans to begin enrolment in phase II GENERATION HD2 trial for Huntington's disease in early 2023